Ann Subashi is a Director in Global CMC within Regulatory at Pfizer where she supports investigational and commercial programs for Pfizer’s biotherapeutics products including a variety of recombinant proteins, antibody drug conjugates and monoclonal antibodies. In addition, Ann has been a member of several internal and external councils and groups focused on QbD, specification setting, CPV and comparability.
Ann has been with Pfizer for over 20 years where she started in Bioprocess R&D focused on process development for veterinary vaccine and human health biologics products. Ann moved into the Protein and Peptide Chemistry group within discovery where she supported protein purification and biophysical characterization support to discovery research projects before transitioning into her current role.
Ann Subashi received her BA in Biology from Brandeis University and MA from Brown University in Biological Sciences.